Inquiry Basket
Loading ......
Certolizumab pegol is a unique biotherapeutic agent that combines the specificity of monoclonal antibody technology with the extended pharmacokinetic properties of polyethylene glycol (PEG) conjugation. Unlike conventional monoclonal antibodies that are full-length immunoglobulin G (IgG) molecules, Certolizumab pegol is a pegylated Fab' fragment derived from a humanized anti-tumor necrosis factor-alpha (TNF-α) antibody. This distinctive structure lacks the Fc region found in traditional antibodies, conferring unique pharmacological properties that differentiate it from other anti-TNF agents. Tumor necrosis factor-alpha is a pro-inflammatory cytokine that plays a central role in the pathogenesis of several chronic inflammatory diseases. Overproduction of TNF-α drives synovial inflammation and joint destruction in rheumatoid arthritis, transmural inflammation in Crohn's disease, and spinal inflammation in ankylosing spondylitis. By neutralizing TNF-α activity, Certolizumab pegol interrupts this inflammatory cascade, reducing symptoms, preventing structural damage, and improving quality of life for patients with these debilitating conditions.The successful clinical use of Certolizumab pegol depends on robust bioanalytical methods to support pharmacokinetic studies and therapeutic monitoring. As with all biotherapeutic products, patients may develop anti-drug antibodies that can alter drug pharmacokinetics and reduce efficacy. Accurate quantification of Certolizumab pegol concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response.
Figure 1.Validated Certolizumab Pegol ELISA Assay for Inflammatory Drug Monitoring.
Tumor necrosis factor-alpha is a pleiotropic cytokine produced primarily by activated macrophages, T cells, and natural killer cells. TNF-α exists in both membrane-bound and soluble forms, both of which are biologically active. The cytokine binds to two distinct receptors, TNFR1 (p55) and TNFR2 (p75), which are expressed on a wide variety of cell types. Upon receptor binding, TNF-α triggers intracellular signaling cascades that lead to the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase pathways. These signaling events result in the production of additional pro-inflammatory cytokines, chemokines, adhesion molecules, and matrix-degrading enzymes. The net effect is amplification of the inflammatory response, recruitment of immune cells to sites of inflammation, and tissue destruction. In rheumatoid arthritis, TNF-α drives the proliferation of synovial fibroblasts, activation of osteoclasts, and degradation of cartilage and bone. In Crohn's disease, TNF-α contributes to the transmural inflammation that characterizes the condition, leading to strictures, fistulas, and abscess formation. Neutralization of TNF-α has therefore become a cornerstone of treatment for these and other inflammatory conditions.
Certolizumab pegol is fundamentally different from other anti-TNF agents. While infliximab, adalimumab, golimumab, and etanercept are all full-length immunoglobulin molecules or Fc fusion proteins, Certolizumab pegol is a pegylated Fab' fragment. The Fab' fragment is derived from a humanized anti-TNF-α antibody, providing high affinity and specificity for TNF-α. The absence of the Fc region has several pharmacological consequences. Certolizumab pegol does not engage Fc gamma receptors, so it does not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. This may contribute to a differentiated safety profile. Additionally, Certolizumab pegol does not undergo Fc receptor-mediated transplacental transfer, making it a preferred option during pregnancy. The polyethylene glycol moiety is covalently attached to the Fab' fragment. PEGylation increases the hydrodynamic volume of the molecule, reducing renal clearance and extending the half-life from hours to approximately two weeks. This extended half-life enables convenient subcutaneous administration every two to four weeks, comparable to other anti-TNF agents.
TNF-α inhibitor therapeutics require rigorous bioanalytical monitoring due to their unique dose-efficacy correlation and variable patient drug exposure. Certolizumab pegol's PEGylated Fab structure differentiates it from conventional anti-TNF antibodies, creating unique detection challenges that generic assays cannot address. Accurate distinction between free and total drug levels is the core foundation of reliable inflammatory drug monitoring. Free certolizumab pegol represents the biologically active drug fraction that binds soluble and membrane-bound TNF-α to block inflammatory signaling pathways. Changes in free drug concentration directly correlate with disease activity, clinical remission rates, and treatment response, serving as a critical PD biomarker for inflammatory disease management. In contrast, total certolizumab pegol concentrations reflect overall systemic drug exposure, supporting comprehensive PK profiling to evaluate drug absorption, distribution, metabolism, and elimination in patients. Without differentiated detection of free and total drug, researchers and clinicians cannot accurately interpret drug efficacy, explain treatment failure, or optimize personalized dosing strategies.
| Product Overview | Details |
| Free Certolizumab Pegol ELISA Kit | The Free Certolizumab Pegol ELISA Kit is specifically designed for the quantitative determination of unbound, functionally active Certolizumab pegol in human serum or plasma. This kit measures the pharmacologically active fraction of drug available for TNF-α neutralization. Key Features
|
| Total Certolizumab Pegol ELISA Kit | The Total Certolizumab Pegol ELISA Kit is designed for the quantitative determination of total Certolizumab pegol concentrations in human serum or plasma, including both free drug and drug bound to TNF-α. Key Features Complete Exposure Assessment: Detects both unbound and TNF-α-bound Certolizumab pegol for comprehensive drug exposure measurement Acid Dissociation Step: Incorporates controlled acid treatment to release antibody from TNF-α complexes without compromising detection or affecting the PEG moiety High Sensitivity: Quantifies total Certolizumab pegol at low ng/mL levels Wide Dynamic Range: Accommodates samples from all time points across the dosing interval |
Certolizumab pegol is a unique pegylated anti-TNF therapy that offers distinct pharmacological properties compared to conventional monoclonal antibodies. Its Fab' fragment structure and PEG conjugation provide an extended half-life and absence of Fc-mediated functions. The successful clinical use of Certolizumab pegol depends on robust bioanalytical methods to support pharmacokinetic characterization and therapeutic monitoring. The Free Certolizumab Pegol ELISA Kit measures the pharmacologically active fraction of drug available for TNF-α neutralization, providing critical information for understanding drug activity. The Total Certolizumab Pegol ELISA Kit provides comprehensive exposure assessment including both free and TNF-α-bound drug. Together, these two kits provide a complete bioanalytical toolkit for researchers and clinicians working with Certolizumab pegol across all stages of development and clinical use.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25012 | Free Certolizumab pegol ELISA Kit | / | Human | / | sELISA | Inquiry |
| DEIA-JY25032 | Total Certolizumab pegol ELISA Kit | / | Human | / | sELISA | Inquiry |
| DEIA-JY25050 | Anti-Certolizumab pegol ELISA Kit | / | Human | / | sELISA | Inquiry |
| DEIA-JY2148 | Anti-Certolizumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY2149 | Certolizumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
